The Pharmacist's Role in Improving the Clinical Outcomes of Patients with Schizophrenia

Pharmacy TimesMarch 2015 Central Nervous System
Volume 81
Issue 3

This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.

The Pharmacist’s Role in Improving the Clinical Outcomes of Patients with Schizophrenia


Tammie Lee Demler, BS, PharmD, MBA, BCPP

Director of Pharmacy Services and Residency Training

New York State Office of Mental Health

The Buffalo Psychiatric Center

Clinical Associate Professor,

University of Buffalo, School of Pharmacy and Pharmaceutical Sciences

Clinical Assistant Professor,

D’Youville College of Pharmacy

Clinical Assistant Professor,

University of Florida, School of Pharmacy, Gainesville, Florida

Educational Objectives:

After completing this continuing education program, the participant will be able to:

  • Examine the epidemiology, pathophysiology, and clinical progression of schizophrenia
  • Describe common adverse events that often accompany schizophrenia therapies, and strategies for monitoring and mitigating these effects
  • Identify issues affecting the successful management of schizophrenia
  • Examine the pharmacist’s role for improving clinical outcomes in schizophrenia

Target audience:


Type of activity:


Release date:

March 6, 2015

Expiration date:

March 6, 2017

Estimated time to complete activity:

2.0 hours

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-15-017-H01-P. The activity is available for CE credit through March 6, 2017.

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.